one8zero8 LLC Has $2.06 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV)

by · The Cerbat Gem

one8zero8 LLC decreased its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 15.5% during the 1st quarter, Holdings Channel reports. The firm owned 9,849 shares of the company’s stock after selling 1,800 shares during the quarter. one8zero8 LLC’s holdings in AbbVie were worth $2,064,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. EnRich Financial Partners LLC increased its stake in shares of AbbVie by 196.4% in the fourth quarter. EnRich Financial Partners LLC now owns 166 shares of the company’s stock valued at $29,000 after buying an additional 110 shares in the last quarter. Abound Financial LLC bought a new stake in AbbVie during the 1st quarter worth about $30,000. Prudent Man Investment Management Inc. acquired a new stake in AbbVie in the 4th quarter valued at about $32,000. Siemens Fonds Invest GmbH increased its position in AbbVie by 197.6% in the 4th quarter. Siemens Fonds Invest GmbH now owns 179,440 shares of the company’s stock valued at $32,000 after acquiring an additional 119,141 shares in the last quarter. Finally, Cypress Capital Management LLC WY acquired a new position in shares of AbbVie during the first quarter worth approximately $35,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Trading Down 0.3%

ABBV opened at $190.22 on Friday. The firm’s fifty day moving average is $187.62 and its two-hundred day moving average is $189.77. The firm has a market cap of $336.00 billion, a PE ratio of 80.94, a price-to-earnings-growth ratio of 1.26 and a beta of 0.48. AbbVie Inc. has a twelve month low of $163.81 and a twelve month high of $218.66. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Friday, April 25th. The company reported $2.46 EPS for the quarter, topping the consensus estimate of $2.40 by $0.06. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The business had revenue of $13.34 billion for the quarter, compared to the consensus estimate of $12.91 billion. During the same quarter last year, the business posted $2.31 EPS. The firm’s revenue was up 8.4% compared to the same quarter last year. Equities research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be given a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.45%. The ex-dividend date of this dividend is Tuesday, July 15th. AbbVie’s dividend payout ratio is currently 279.15%.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. BNP Paribas raised shares of AbbVie to a “hold” rating in a report on Thursday, May 8th. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 22nd. Guggenheim boosted their target price on AbbVie from $214.00 to $216.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. Cantor Fitzgerald started coverage on AbbVie in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $210.00 price target on the stock. Finally, Morgan Stanley lifted their price objective on AbbVie from $241.00 to $250.00 and gave the stock an “overweight” rating in a research report on Monday, April 28th. Eight analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $211.29.

View Our Latest Stock Analysis on AbbVie

AbbVie Profile

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Recommended Stories

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).